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Summary
Background Most malaria deaths occur in rural areas. Rapid progression from illness to death can be interrupted by 
prompt, eﬀ ective medication. Antimalarial treatment cannot rescue terminally ill patients but could be eﬀ ective if 
given earlier. If patients who cannot be treated orally are several hours from facilities for injections, rectal artesunate 
can be given before referral and acts rapidly on parasites. We investigated whether this intervention reduced mortality 
and permanent disability.
Methods In Bangladesh, Ghana, and Tanzania, patients with suspected severe malaria who could not be treated orally 
were allocated randomly to a single artesunate (n=8954) or placebo (n=8872) suppository by taking the next numbered 
box, then referred to clinics at which injections could be given. Those with antimalarial injections or negative blood 
smears before randomisation were excluded, leaving 12 068 patients (6072 artesunate, 5996 placebo) for analysis. 
Primary endpoints were mortality, assessed 7–30 days later, and permanent disability, reassessed periodically. All 
investigators were masked to group assignment. Analysis was by intention to treat. This study is registered in all 
three countries, numbers ISRCTN83979018, 46343627, and 76987662. 
Results Mortality was 154 of 6072 artesunate versus 177 of 5996 placebo (2·5% vs 3·0%, p=0·1). Two versus 13 
(0·03% vs 0·22%, p=0·0020) were permanently disabled; total dead or disabled: 156 versus 190 (2·6% vs 3·2%, p=0·0484). 
There was no reduction in early mortality (56 vs 51 deaths within 6 h; median 2 h). In patients reaching clinic within 6 h 
(median 3 h), pre-referral artesunate had no signiﬁ cant eﬀ ect on death after 6 h or permanent disability 
(71/4450 [1·6%] vs 82/4426 [1·9%], risk ratio 0·86 [95% CI 0·63–1·18], p=0·35). In patients still not in clinic after 
more than 6 h, however, half were still not there after more than 15 h, and pre-referral rectal artesunate signiﬁ cantly 
reduced death or permanent disability (29/1566 [1·9%] vs 57/1519 [3·8%], risk ratio 0·49 [95% CI 0·32–0·77], 
p=0·0013).
Interpretation If patients with severe malaria cannot be treated orally and access to injections will take several hours, 
a single inexpensive artesunate suppository at the time of referral substantially reduces the risk of death or permanent 
disability.
Funding UNICEF/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases 
(WHO/TDR); WHO Global Malaria Programme (WHO/GMP); Sall Family Foundation; the European Union 
(QLRT-2000-01430); the UK Medical Research Council; USAID; Irish Aid; the Karolinska Institute; and the University 
of Oxford Clinical Trial Service Unit (CTSU).
Introduction
Death and permanent disability from malaria are 
avoidable by prompt, eﬀ ective treatment.1 Malaria can, 
however, progress from fever to life-threatening disease 
within hours, and some people who survive severe 
malaria sustain substantial permanent damage to the 
CNS.2–5 The only way to give eﬀ ective antimalarial 
treatment to patients in the community who cannot be 
treated orally is to take them to a health-care facility (eg, 
hospital, dispensary, or other clinic) at which injections 
can be given. From an isolated rural village, however, 
reaching such a clinic can take many hours, or even 
days, by which time the disease may have progressed 
too far to be treated successfully. An inexpensive 
artesunate suppository has therefore been developed 
that can be given rectally at, or near, home by a parent, 
neighbour, or community health worker when severe 
malaria is suspected, reducing time to treatment. It 
could also replace some antimalarial injections in 
clinics.
Artemisinins act more rapidly than other classes of 
antimalarial drugs do. Artesunate reduces parasitaemia 
within hours, acting on both mature and young parasites.6 
Hospital-based studies have shown that a single dose of 
artesunate, given rectally, can provide parasiticidal blood 
concentrations within 10–20 min, and can halve 
parasitaemia numbers within 6–12 h.7–9 If a severely ill 
patient is given rectal artesunate in the community, 
however, referral to a medical facility is still needed for 
diagnosis and treatment. For, even in malaria-endemic 
areas, symptoms that are thought to be due to severe 
malaria could well be found to be due to another potentially 
Lancet 2009; 373: 557–66
Published Online
December 8, 2008
DOI:10.1016/S0140-
6736(08)61734-1
See Comment page 522
*Members listed at end of paper
UNICEF/UNDP/World Bank/
WHO Special Programme for 
Research and Training in 
Tropical Diseases, Geneva, 
Switzerland (M F Gomes PhD, 
Prof P Olliaro MD); Ministry of 
Health and Family Welfare, 
Government of the People’s 
Republic of Bangladesh, 
Mohakhali, Dhaka, Bangladesh 
(Prof M A Faiz PhD); Health 
Research Unit, Ghana Health 
Service, Accra, Ghana 
(Prof J O Gyapong MD); Case 
Management and Research, 
Global Malaria Programme, 
WHO, Geneva, Switzerland 
(M Warsame MD); Kwame 
Nkrumah University of Science 
and Technology, School of 
Medical Sciences, Kumasi, 
Ghana (Prof T Agbenyega MD); 
MRC HIV Clinical Trials Centre, 
London, UK 
(Prof A Babiker PhD); WHO, 
The WHO Representative 
Oﬃ  ce, Dar es Salaam, Tanzania 
(F Baiden MD); Chittagong 
Medical College, Chittagong, 
Bangladesh 
(Prof E B Yunus MD); School of 
Public Health, University of 
Ghana, Accra, Ghana 
(Prof F Binka MD); Dodowa 
Health Research Centre, 
Dodowa, Ghana (C Clerk MD); 
Medical Research Council, 
Cape Town, South Africa 
(Prof P Folb FRS); Malaria 
Research Group, Chittagong 
Medical College, Chittagong, 
Bangladesh (R Hassan MD, 
Prof M A Hossain MD, 
R Samad MD); National 
Institute of Medical Research, 
Dar es-Salaam, Tanzania 
(O Kimbute MA, Prof A Kitua MD, 
C Makasi MD, Z Mrango MD); 
St George’s Hospital Medical 
School, London UK 
(Prof S Krishna MD); 
Articles
558 www.thelancet.com   Vol 373   February 14, 2009
lethal infection (eg, pneumonia) that requires diﬀ erent 
treatment. Moreover, one pre-referral dose of artesunate is 
not a complete treatment for severe malaria, and fully 
curative treatment can best be undertaken at a clinic with 
facilities for antimalarial injections and supportive care.
Prompt eﬀ ective treatment of severe malaria should 
limit or prevent permanently disabling neurological 
damage,4,5 but treatment of severe disease could prevent 
death in some patients who already have irreversible 
brain damage, leaving them alive but permanently 
disabled. Furthermore, protracted exposure to high doses 
of lipid-soluble analogues of artesunate has caused 
neurological damage in animal experiments.10 Hence, 
the net eﬀ ects of pre-referral rectal artesunate not only 
on mortality but also on severe and persistent neurological 
sequelae needed to be assessed.
We report a community-based placebo-controlled trial 
of rectal artesunate versus placebo in patients with 
suspected severe malaria who could not take medication 
orally and were not at a clinic at which injections could 
be given. The main objective was to determine whether, 
in these circum stances, rectal artesunate plus referral to 
such a clinic reduced mortality and permanent disability 
compared with rectal placebo plus referral.
Methods
Patients, procedures, and study setting
The study took place in 291 rural villages in Ghana, 
Tanzania, and Bangladesh. Patients were eligible for 
randomisation if they were thought by the recruiter to 
have malaria and could not be treated orally.
Locally resident village recruiters (268 in 142 villages in 
Africa, 149 in 149 villages in Bangladesh), most with little 
previous medical knowledge and no research experience, 
underwent training and recruited patients in their 
communities on the basis of clinical symptoms. Recruiters 
were visited every few days by 74 ﬁ eld supervisors 
throughout the study (Aug 3, 2000–July 30, 2006). For 
patients meeting eligibility criteria, consent was signed 
(or ﬁ ngerprinted) by caretakers and witnessed, a brief 
entry form was completed, a peri pheral blood smear was 
generally sought by the recruiter for later parasitology, 
and the next numbered treatment box was used. (Boxes 
for individuals were packed into block-balanced cartons 
of eight or four random allo cations, computer generated 
by the Oxford Clinical Trial Service Unit, UK.) Each box 
contained computer- generated identiﬁ cation labels for 
forms and any blood slides, and, sealed in a waterproof 
sachet, one artesunate or placebo suppository of identical 
appearance. (Bulk artesunate, Abbott, Liestal, Switzerland; 
encapusaltion, Scherer capsules, Eberbach, Germany; 
sealing, Scan pharm packaging, Copenhagen, Denmark.) 
All study staﬀ  remained masked to the treatment 
allocation until the endpoints had been ﬁ nalised on 
Sept 19, 2006, and the study was unblinded.
The suppository was inserted into the rectum and the 
buttocks held together for about 10 min to help prevent 
expulsion. On successful insertion, the patient was in 
the study even if the suppository was later expelled. 
Re-randomisation within 30 days was disallowed (ﬁ ve 
smear-positive patients: all recovered). After insertion, 
the patient was to go to a clinic at which injections could 
be given. Two blood slides were taken in Asia; the extra 
one accompanied the patient to hospital. 
The three African study sites were all in high malaria 
transmission areas, and they recruited only young 
children aged 6–72 months. The Asian study site was in 
a low unstable transmission area and recruited older 
patients as well. The main diﬀ erence between the 
African and Asian settings was, however, in the rapidity 
and nature of clinical care. In Africa, many patients 
were still not in clinic more than 6 h after randomisation, 
the ﬁ rst health facility for injections was often just a 
dispensary, and injection on arrival was usually 
intramuscular. In Asia, the ﬁ rst facility was a hospital 
oﬀ ering study patients free, immediate admission and 
treatment at any hour, and special arrangements had 
been made to ensure free reliable availability and 
prompt use of intravenous quinine and other 
appropriate treatment, including broad-spectrum 
antibiotics and supportive care. Hence, patients in 
Bangladesh went to hospital rapidly and mortality was 
17 826 patients with suspected malaria, unable to be treated  orally; consent
signed; blood smear (93% taken); and  suppository inserted, thereby
randomising the patient
8954 allocated artesunate
 0 lost to follow-up
6072 analysed for death
 and disability
5996 analysed for death
 and disability
8872 allocated placebo
 8 lost to follow-up
  (but assumed alive)
2330 smear negative 
  for malaria;*
  69 died (18 ≤6 h), 
        9 disabled
2318 smear negative 
  for malaria;*
  78 died (19 ≤6 h), 
    9 disabled
552 with prior antimalarial 
  injection;*
  35 died (12 ≤6 h), 
   4 disabled
558 with prior antimalarial 
  injection;*
  33 died (15 ≤6 h), 
    0 disabled
12 068 patients analysed
After the 7–30 day follow-up, further follow-up was only for the few (<1%) 
with neurological damage recorded at day 7–30, to see whether this damage 
was clinically conﬁrmed and whether it eventually resolved or was permanent
Figure 1: Trial proﬁ le
Main 7–30 day follow-up was at a median of 14 days after randomisation. 
*Randomised patients were excluded only if a prerandomisation blood smear 
was free of malaria parasites (26% of all smears were negative for malaria); or 
the entry form recorded that an antimalarial drug had already just been injected. 
In patients with smear-negative disease who were still alive but not injected or 
in clinic more than 6 h after randomisation, 28/475 artesunate-allocated 
vs 25/472 placebo-allocated patients died or were disabled. 
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low; time to arrival was typically a couple of hours after 
randomisation and time to discharge was typically 
about 3 days.
Before the study began in a village, it was explained to 
leaders, traditional healers, and the community, usually 
culminating in a large public village meeting at which 
the individual consent form, use of placebo, and 
importance of proceeding to the referral clinic were 
discussed in detail, and the trained local village recruiters 
were introduced. International monitors veriﬁ ed that 
selected villagers did understand the study. The trial was 
approved by national ethics committees and the WHO 
ethics committee, and was reviewed regularly by an 
independent data moni toring committee.
Outcomes
Primary endpoints were mortality and permanent 
disability. Mortality was to be assessed (usually at home) 
7–30 days after randomisation. Patients had to be reliably 
reported as dead or seen alive. For the few (141/17 826 [1%]) 
for whom neither was possible, an apparently reliable 
report (usually from a family member or near neighbour) 
of recovery was acceptable. Only eight (<0·1%) 
participants, all allocated placebo, were completely lost; 
all are assumed to have recovered and survived. At the 
7–30 day follow-up, a questionnaire about possible 
neurological damage in survivors was administered. 
Patients with new problems that might be an indicator 
of neurological damage were assessed by a study clinician 
whose decision was ﬁ nal as to whether there was 
substantial damage from the index episode or its 
treatment. Only patients with clinically conﬁ rmed 
neurological damage were followed up further. A study 
clinician revisited them periodically until the symptoms 
resolved, the patient died, or the study ended. 
Classiﬁ cation as resolved, resolving, or persistent was 
made before unblinding.
There was, by deﬁ nition, no overlap between 7–30 day 
mortality and neurological damage (although a few later 
deaths were attributed to such damage). For patients 
with either endpoint, a study clinician recorded narratives 
of the main events before and after randomisation, 
including time to reach clinic and time to death, on the 
basis of any clinical records plus a structured interview 
with the family. A blinded endpoint review committee 
(ERC) ﬁ nalised time to reach clinic (ie, time to reach a 
facility at which injections could be given), time to death, 
and which few endpoints were deﬁ nitely not due to the 
index episode of malaria.
Quality assurance
Cartons of boxes were replaced if nearly empty, and the 
number of treatments used was checked against the 
entry forms completed; any discrepancies were investi-
gated. Only one box (placebo) remained un accounted 
for; we assumed it was used and that that placebo-
allocated patient recovered. At intervals through out the 
trial, ﬁ eld samples of study capsules were blindly 
analysed quantitatively, showing no loss of potency or 
errors of packaging. As a further check for errors of 
packaging for the study drug for older patients, all 
artesunate or placebo 400 mg capsules remaining at the 
end of the study were blindly analysed qualitatively, 
again showing no errors.
Artesunate Placebo
Number of 
patients 
entered
(N=6072)
Percentage never 
went to a clinic
(7·8% [470/6015])
Number of 
patients 
entered
(N=5996)
Percentage never 
went to a clinic
(6·9% [411/5945])
Parasite species at baseline 
Africa 3041 (50%) 13·6% (407/2999) 2999 (50%) 12·5% (370/2960)
P falciparum only 2532 12·2% (305/2502) 2476 11·0% (269/2449)
P ovale only 2 .. 1 ··
P malariae only 5 .. 4 ··
No blood slide* 502 20·8% (102/490) 518 19·8% (100/506)
Asia 3031 (50%) 2·1% (63/3016) 2997 (50%) 1·4% (41/2985)
P falciparum only 2369 1·9% (44/2356) 2335 1·4% (33/2325)
P falciparum and P vivax 60 .. 61 ··
P vivax only 598 2·7% (16/597) 597 1·0% (6/597)
No blood slide 4 .. 4 ··
Parasite density per μL
<5000 1456 (26%) 7·4% (107/1442) 1370 (25%) 6·7% (91/1353)
5000–25 000 1404 (25%) 6·5% (91/1398) 1492 (27%) 6·1% (91/1487)
>25 000 2706 (49%) 6·3% (168/2681) 2612 (48%) 4·9% (127/2595)
Parasitology unknown* 506 21·1% (104/494) 522 20·0% (102/510)
Clinical status at entry†
Coma 497 (8%) 7·9% (37/467) 483 (8%) 8·1% (37/458)
Repeated convulsions 1248 (21%) 6·3% (78/1237) 1186 (20%) 6·0% (71/1174)
Other 4327 (71%) 8·2% (355/4311) 4327 (72%) 7·0% (303/4313)
Gender
Female 2747 (45%) 8·3% (225/2719) 2757 (46%) 7·7% (211/2732)
Male 3324 (55%) 7·4% (244/3295) 3238 (54%) 6·2% (199/3212)
Unknown 1 .. 1 ··
Artesunate dose tested and age 
100 mg (age 6–72 months‡) 4063 (67%) 10·6% (427/4016) 3987 (66%) 9·8% (385/3941)
Handeni, Tanzania, 2002–06 726 18·9% (133/704) 737 18·3% (131/716)
Kilosa, Tanzania, 2000–06 1170§ 18·7% (217/1159) 1169 16·5% (192/1163)
Navrongo, Ghana, 2000–04 1145 5·0% (57/1136) 1093 4·4% (47/1081)
Chittagong, Bangladesh, 
2000–04
1022 2·0% (20/1017) 988§ 1·5% (15/981)
400 mg (age >72 months; 
Chittagong only, 2000–04)
2009 (33%) 2·2% (43/1999) 2009 (34%) 1·3% (26/2004)
6–14 years 605 1·5% (9/602) 618 1·5% (9/614)
15–24 years 654 2·0% (13/652) 636 0·9% (6/636)
≥25 years 750 2·8% (21/745) 755 1·5% (11/754)
Since early death can prevent arrival at clinic, non-adherence (percentage who never went to a clinic at which 
treatment could be injected) was calculated only in those surviving more than 6 h. *At one site (Handeni), blood 
smears were not collected during most of the trial. †Deﬁ ned by a question about coma at three study sites and a 
question about altered consciousness at Handeni: risks were comparable. ‡Apparent age 6–60 months in Tanzania, 
6–72 months elsewhere; overall, the mean age was 20 months for those randomly assigned to the 100 mg dose of 
artesunate. §Only two case report forms were missing, one from each group; the child allocated to artesunate 
recovered fully and the analyses assume both did. 
Table 1: Baseline characteristics and non-adherence with referral advice, by treatment allocation
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Parasites were counted on Giemsa-stained slides until 
at least 200 white cells or 500 parasites had been counted. 
Parasite density per μL was taken as 8000 times the ratio 
of asexual parasites to white cells. A slide was declared 
negative only if no parasites were seen after examination 
of at least 500 white cells.
Statistical methods
We analysed results with Stata (version 9.2). Proportions 
were compared by χ² tests. All p values are two-sided. 
The main analyses are of mortality by the 7–30 day 
follow-up and of permanent disability (primary 
endpoints). The indication for rectal artesunate that the 
study evaluated (as ﬁ led with the US Food and Drug 
Administration at the start of the study) was for “the 
initial management of acute malaria…in patients who 
cannot take medication by mouth and for whom 
parenteral treatment is not available.” Hence, it was 
decided before the results were unblinded to exclude 
patients if a blood smear just before randomisation was 
reliably classiﬁ ed as having no malaria parasites, or the 
randomisation form recorded an immediately previous 
antimalarial injection (ﬁ gure 1). The analyses are of all 
other patients into whom a trial capsule was inserted 
(ie, by intention to treat), even though the capsule was 
quickly expelled in eight who died later (four artesunate, 
four placebo).
This study is registered in Bangladesh, Ghana, and 
Tanzania, numbers ISRCTN83979018, 46343627, and 
76987662.
Role of the funding sources 
The external funding sources of the study had no role in 
study design, data collection, data analysis, interpretation, 
or writing of the report. The corresponding author had 
full access to the data and ﬁ nal responsibility for 
submission for publication. 
Results
A trial suppository was inserted in 17 826 patients, but 
after the prespeciﬁ ed exclusions of 4648 with a negative 
blood smear before randomisation and a further 
1110 with an anti malarial injection before randomisation 
(ﬁ gure 1), the main analyses are of death or perma nent 
disability in 12 068 patients with malaria, 6072 randomly 
allocated artesunate and 5996 placebo. The baseline 
characteristics were well balanced (table 1). Half the 
patients were in Africa and half in Asia: in both 
continents Plasmodium falciparum predominated 
(table 1). Of positive blood smears, 5318 (48·2%) had 
more than 25 000 parasites per μL (table 1). Overall, 
0
0
1
2
3
4
Pa
tie
nt
s (
%
)
5
1 2
Africa
Asia
3 4
Dead, placebo
Dead, artesunate
Dead or disabled, placebo
Dead or disabled, artesunate
6 h from randomisation
5
Days since randomisation
6 7 7–30
1·5%
3·6%
3·7%
4·4%
4·8%
Figure 2: Death by time since randomisation and death or permanent disability at the 7–30 day follow-up
 Africa (three study sites) Asia (one study site) All four study sites
Artesunate 
(N=3041)
Placebo 
(N=2999)
Artesunate 
(N=3031)
Placebo 
(N=2997)
Artesunate 
(N=6072)
Placebo  
(N=5996)
Signiﬁ cance
Death by 7–30 day follow-up*
Death in 0–6 h (at a median of 2 h) 42 39 14 12 56 51 NS
Reached clinic in 0–6 h (~3 h†), died after hour 6 42 47 29 28 71 75 NS
Still not in clinic at 6 h (~15 h†), died after hour 6 25 47 2 4 27 51 p=0·0039
Alive at 7–30 day follow-up, but with permanent disability‡
CNS HIV or CNS tuberculosis 1 0 0 1 1 1 NS
Sequelae of cerebral malaria 1 12 0 0 1 12 p=0·0020
Overall
Death/permanent disability 111 (3·6%) 145 (4·8%) 45 (1·5%) 45 (1·5%) 156 (2·6%) 190 (3·2%) p=0·0484
NS=not signiﬁ cant. *Seven vs seven of the deaths (all in Africa) could not have been aﬀ ected by the trial capsule (four vs four patients: capsule expelled intact and not 
re-inserted, plus three vs three patients: death attributed blindly by endpoint review committee to a disease other than malaria). †Median time (for those with an adverse 
outcome) to arrival at clinic, or prior death (ie, death without arrival at clinic). ‡One vs one permanent disability could not have been aﬀ ected by trial capsule (one HIV CNS 
disease in Africa, one tuberculosis meningitis in Asia; both died after 7–30 day follow-up). All other cases of permanent disability were from CNS malaria in children in Africa, 
and all were severe; ﬁ ve, all in the placebo group, died after 7–30 day follow-up.
Table 2: Eﬀ ects of trial treatment on early and later mortality and on permanent disability in Africa (three study sites), Asia (one study site), and all 
four study sites
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980 (8%) patients were comatose, a further 2434 (20%) 
had had convulsions, and most others were prostrated 
by their illness (table 1). All patients in Africa and a third 
of those in Asia had an assessed age of 6–72 months.
Randomisation was by successful rectal insertion of 
the trial capsule containing artesunate or placebo. Almost 
all Asian patients then went to hospital, arriving shortly 
after randomisation, but a substantial minority in Africa 
never went to a clinic (table 1), or arrived after a delay of 
several hours. The main reasons given for delay were 
that randomisation took place too late in the day for 
travel, or that it took time for the parents to gather funds 
for the trip or treatment. Artesunate had only a slight 
eﬀ ect on attendance; in those who survived more than 
6 h, the proportions who never reached clinic were 7·8% 
artesunate and 6·9% placebo (p=0·03 in an analysis 
stratiﬁ ed for study site; table 1). Mean duration of hospital 
stay (available only in Asia) was 3·13 days with artesunate 
versus 3·20 days with placebo (SD 0·94; p=0·004).
Figure 2 shows, for Africa and Asia separately, 
treatment-speciﬁ c mortality during the ﬁ rst 7 days after 
randomisation, and at the 7–30 day follow-up (which 
took place, on average, at day 14). (CNS damage that 
resulted in permanent disability was considered 
comparable in importance with death, but CNS damage 
that eventually resolved was not.) In Asia, where patients 
reached eﬀ ective hospital treatment quickly, mortality 
was low and seemed to be unaﬀ ected by rectal artesunate. 
In Africa, where delays were often longer and pre-
referral rectal artesunate had a longer time in which to 
act alone, it appeared to improve outcome (ﬁ gure 2).
The main aim of pre-referral rectal treatment in this 
study was to bring forward by some hours the control of 
parasitaemia. For patients who reached a clinic (or died) 
within a few hours of randomisation, only a short time 
was gained by pre-referral treatment, but for patients 
who took longer to reach a clinic, many hours could be 
gained. Table 2 subdivides the deaths both by time to 
death and by the time taken to reach clinic, and provides 
results separately for Africa, Asia, and all study sites.
In the overall results there was no signiﬁ cant eﬀ ect of 
pre-referral rectal artesunate on the numbers of deaths 
within 6 h of randomisation (56 artesunate vs 51 placebo; 
median time to death only 2 h [IQR 1–3]), or on the 
numbers of later deaths in those who reached clinic 
within 0–6 h (71 artesunate vs 75 placebo; median time 
to clinic only 3 h [IQR 1–4]). In patients who had still not 
reached clinic after more than 6 h, about half still had 
not done so after more than 15 h, giving the trial 
treatment allocation long enough to have a substantial 
eﬀ ect on the malaria parasites. In these patients, pre-
referral rectal artesunate reduced mortality signiﬁ cantly 
(27 artesunate vs 51 placebo deaths; p=0·0039). All these 
78 deaths were of young children (age 6–72 months, 
median 17 months [IQR 10–24]), and 72 (92%) were in 
Africa.
Table 2 also shows the numbers who, although still 
alive at the 7–30 day follow-up, were permanently disabled 
by other diseases or by neurological sequelae of the 
original episode of malaria (or its treatment). One patient 
given artesunate versus 12 given placebo had permanent 
disability from cerebral malaria (p=0·0020, all children 
Risk of death in 0–6 h 
(median 2 h) for all patients
Risk of later death/disability (if survived >6 h)*
Reached clinic in 0–6 h?
Artesunate Placebo Yes (~3 h†) No (~15 h‡)
Artesunate Placebo Artesunate Placebo
Africa (age 6–72 months)
Handeni, Tanzania 22/726 21/737 15/286 17/292 17/418 33/424
Kilosa, Tanzania 11/1170 6/1169 8/542 11/539 8/617 14/624
Navrongo, Ghana 9/1145 12/1093 19/816 26/798 2/320 5/283
All in Africa 42/3041 (1·4%) 39/2999 (1·3%) 42/1644 (2·6%) 54/1629 (3·3%) 27/1355 (2·0%) 52/1331 (3·9%)
Chittagong, Asia (by age)
6–72 months 5/1022 7/988 7/947 19/918 2/70 5/63
Older child/adult 9/2009 5/2009 22/1859 9/1879 0/141 0/125
All in Asia 14/3031 (0·5%) 12/2997 (0·4%) 29/2806 (1·0%) 28/2797 (1·0%) 2/211 (0·9%) 5/188 (2·7%)
Total
Africa and Asia 56/6072 (0·94%) 51/5996 (0·85%) 71/4450 (1·6%) 82/4426 (1·9%) 29/1566 (1·9%) 57/1519 (3·8%)
Relative risk (95% CI) 1·10 (0·75–1·61) 0·86 (0·63–1·18) 0·49 (0·32–0·77) 
p value§ 0·61 0·35 0·0013
*Denominators=numbers surviving more than 6 h after entry, subdivided by whether patient reached clinic in 0–6 h. Time to clinic was recorded in all who died or had 
neurological damage; otherwise, it was recorded routinely only in Kilosa and Navrongo. For those who did not die in Handeni and Chittagong, it was recorded whether they 
reached a clinic. For this table it is assumed that, if they did die, the proportions doing so in 0-6 h were 50% in Handeni and 95% in Chittagong. †For those who reached clinic 
in 0–6 h and then died after hour 6, median time to arrival was 2 h in Chittagong and 4 h in Africa. ‡For those still not in clinic after more than 6 h who died, the median time 
to reach clinic (or to death without reaching clinic) was 15 h. §Relative risk (95% CI) and p value for artesunate versus placebo.
Table 3: Eﬀ ects of trial treatment (artesunate or placebo) on death or permanent disability, subdivided by study site and time taken to reach clinic
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in Africa). Of these children, ﬁ ve eventually died after the 
7–30 day visit (0 artesunate vs ﬁ ve placebo) and eight still 
had severe CNS damage that was considered permanent 
when last assessed. 19 given artesunate vs 12 given 
placebo had CNS damage that resolved (p=0·2). Of those 
with any clinician-conﬁ rmed malarial CNS damage, 
therefore, the proportions that resolved were 19 of 20 for 
artesunate versus 12 of 24 for placebo (p=0·0037 
for diﬀ er ence).
Table 3 and ﬁ gure 3 both combine the results for 
death and permanent disability from table 2, subdividing 
them by time to death and by time taken to reach clinic, 
and relating them to the estimated numbers at risk. As 
in a previous trial of artesunate versus quinine,11 there 
was no apparent eﬀ ect of artesunate on early mortality 
(within 0–6 h; ﬁ gure 3). About three-quarters of patients 
who survived more than 6 h reached a clinic within 
0–6 h; among them, the median time taken to reach 
clinic was about 3 h, and artesunate did not have a 
signiﬁ cant eﬀ ect on outcome (71 vs 82 [1·6% vs 1·9%] 
dead after 6 h or permanently disabled; risk ratio 0·86 
[95% CI 0·63–1·18]; p=0·35). Artesunate did, however, 
have a signiﬁ cant eﬀ ect on outcome in the quarter of 
patients who were still not in clinic more than 6 h after 
randomisation. For them, the probability of death or 
permanent disability was only 1·9% with rectal 
artesunate versus 3·8% with placebo (29 artesunate vs 
57 placebo dead or permanently disabled; risk ratio 0·49 
[95% CI 0·32–0·77]; p=0·0013).
Table 3 subdivides these results by study site and, 
within Asia, by age; the signiﬁ cant treatment eﬀ ect in 
the two right-hand columns is accounted for entirely by 
young children, mostly in Tanzania (where arrival at a 
dispensary or other clinic at which antimalarial injections 
could be given often took several hours). Time to reach 
clinic was recorded for all patients with an adverse 
outcome and was adjudicated, blind to treatment, by the 
ERC. Hence, the numerators (29 vs 57 dead or disabled) 
at the right-hand side of table 3 and ﬁ gure 3 are reliably 
known. Any slight uncertainties in the denominators 
(1566 vs 1519; table 3 footnote) do not materially aﬀ ect 
the p value, the two-fold relative risk, or the 95% CI 
associated with it.
Figure 4 presents the results for Africa and Asia 
separately; the absolute risks were three times as great 
in Africa, partly because all patients were young children 
and almost all parasites were P falciparum. Perhaps 
more importantly, patients in Africa generally took 
longer to reach eﬀ ective treatment, whereas those in 
Asia quickly got intravenous quinine and hospital care. 
Even in patients who reached a clinic within 0–6 h, the 
median time to arrival was about 4 h in Africa and only 
2 h in Asia, and the probability of an adverse outcome 
was about 3% in Africa (42 artesunate vs 54 placebo) and 
only about 1% in Asia (29 artesunate vs 28 placebo).
Although these results from Asia (29 vs 28: ﬁ gure 4) 
suggest little diﬀ erence between artesunate and placebo 
in patients who reach eﬀ ective treatment rapidly, 
subdivision by age suggests a favourable eﬀ ect in young 
children (seven vs 19) but an adverse result in older 
patients (22 vs nine). This apparent interaction with age 
is signiﬁ cant (p=0·0025), but it might nevertheless 
represent just a chance irregularity in circumstances in 
which treatment had too little time to have any material 
eﬀ ect on outcome in either age range. The mean time 
spent in hospital in Asia (artesunate vs placebo) 
was 3·00 versus 3·11 days in young children and 
3·20 versus 3·24 days in older patients (p=0·22 for 
interaction).
Figure 5 subdivides by coma the results for death or 
permanent disability. Of the early deaths within 6 h after 
randomisation, half (54/107) were in the 8% of patients 
who were already comatose. The trial treatment had no 
apparent eﬀ ect on this early mortality. This ﬁ nding does 
not necessarily mean, however, that other comatose 
patients could not beneﬁ t from such treatment. In 
patients still not in clinic more than 6 h after 
randomisation, the absolute beneﬁ t seemed to be 
substantially greater for those in coma when randomised 
(6·7% artesunate vs 13·7% placebo, p=0·07) than for 
those not (1·5% vs 2·8%, p=0·01), but the numbers in 
coma are too small for this result to be reliable. Results 
for those who were not in coma (and, by subtraction from 
table 3, for those in coma) are given in more detail in 
table 4.
In Asia, quinine was given intravenously, but children 
in Africa had intramuscular injections. The 
intramuscular injection site was not systematically 
recorded, but in Tanzania (not Ghana) it was often the 
buttock, and in eight cases this caused serious sciatic 
nerve damage (three artesunate vs ﬁ ve placebo, although 
the trial treatment is unlikely to have aﬀ ected this risk). 
Figure 3: Eﬀ ects of trial treatment on early mortality and, subdivided by 
time taken to reach clinic, later mortality or permanent disability
*Median time to death. †Median time (for those with adverse outcome) to 
arrival at clinic, or prior death.
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All cases resolved without causing permanent disability, 
but some took many months to do so. If we assume that 
about 2000 of the children in Tanzania received 
injections into the buttock, then their absolute risk of 
serious sciatic nerve damage from this was about 
0·4% (which could have been avoided by use of a 
diﬀ erent intramuscular injection site).
Discussion
Death from malaria reﬂ ects delay in administration of 
eﬀ ective antimalarial treatment. Our results provide 
strong evidence that if patients with severe malaria 
cannot be treated orally and referral is likely to take 
several hours, an immediate rectal dose of artesunate 
before referral substantially reduces the risk of death or 
permanent disability. This main ﬁ nding is based on only 
about 3000 of the 18 000 patients originally recruited 
(since some 5000 had a negative blood smear, a further 
1000 had just been injected with an antimalarial drug 
[ﬁ gure 1], and three-quarters of the remaining 
12 000 quickly reached a clinic at which such an injection 
could be given [ﬁ gure 3]).
The time that would be taken to reach clinic appeared 
to be a key determinant of the importance of pre-referral 
treatment. Rectal artesunate takes 6–12 h to produce 
much change in the parasite count,7–9 and, as expected,11 
there was no apparent reduction in early mortality. 
Although artesunate kills parasites in a wider range of 
the parasite life cycle than quinine does, there was no 
signiﬁ cant additional eﬀ ect of the trial treatment on 
outcome in patients who were already at, or only a few 
hours away from, a clinic at which they could be given 
quinine. The lower conﬁ dence limit of 0·63 for the risk 
ratio among such patients means, however, that even in 
these circumstances inclusion of an initial rectal dose of 
artesunate could be of some real value.
Africa
Asia
A
A
B
Ri
sk
 (%
)
Artesunate
vs placebo
p=0·003
0
1
2
3
4
1·4% 1·3%
2·6%
3·3%
2·0%
3·9%
Ri
sk
 (%
)
Artesunate
vs placebo
p=NS
0
1
2
3
4
0·5% 0·4%
1·0% 1·0% 0·9%
2·7%
Yes
(~4 h†)
No
(~15 h†)
Risk of death in
0–6 h (~2h*)
for all patients
Risk of death in
0–6 h (~1 h*)
for all patients
B Risk of later death/disability, if
survived >6 h
Reached clinic in 0–6 h?
Risk of later death/disability, if
survived >6 h
Reached clinic in 0–6 h?
Yes
(~2 h†)
No
(~13 h†)
Artesunate
Placebo
14
3031
42
3041
39
2999
42
1644
27
1355
12
2997
29
2806
2
211
28
2797
54
1629
52
1331
5
188
Figure 4: Eﬀ ects of trial treatment in Africa and in Asia
NS=not signiﬁ cant. *Median time to death. †Median time (for those with 
adverse outcome) to arrival at clinic, or prior death.
Figure 5: Eﬀ ects of trial treatment if comatose and if not comatose
*Median time to death. †Median time (for those with adverse outcome) to 
arrival at clinic, or prior death.
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The risk reduction was statistically deﬁ nite only in the 
3000 patients who were still not at such a clinic after 
more than 6 h; half of these patients were still not there 
after more than 15 h, giving the trial treatment enough 
time to aﬀ ect the progression of the disease substantially 
and thereby achieve a highly signiﬁ cant reduction in 
death or permanent disability. The adverse outcomes 
contributing to this signiﬁ cant result were all among 
young children, mostly in Africa, but that does not mean 
that the results apply only to children, or only to Africa. 
The importance of prompt, eﬀ ective treatment with 
artesunate could well be greater in young children than 
in older patients, however, since acute malaria can 
progress so rapidly in young children that gaining extra 
hours might be particularly important.2
Presumably, the longer the time to clinic, the greater 
the importance of pre-referral treatment. We note that 
the cutoﬀ  of 6 h in our analyses was not prespeciﬁ ed, and 
that this trial should not be taken as showing that pre-
referral artesunate is of substantial beneﬁ t only if the 
time to clinic will be more than exactly 6 h.
Age-speciﬁ c analyses were not prespeciﬁ ed in the 
original trial protocol but the data analysis plan agreed 
before unblinding speciﬁ ed that the main analysis would 
consider young children (assessed age 6–72 months, 
randomised between 100 mg artesunate and placebo) 
separately from older patients (school-aged children or 
adults, randomised between 400 mg artesunate and 
placebo). This separation would not materially aﬀ ect the 
key result among patients still not at clinic more than 
6 h after randomisation, since all with an adverse 
outcome were young children (table 3). Likewise, it 
would not aﬀ ect the results in Africa, where all were 
young children.
In Asia, however, 57 patients (29 artesunate vs 
28 placebo; ﬁ gure 4) reached hospital within 0–6 h, 
should have received intravenous quinine promptly (at a 
median of about 2 h after randomisation), and then died 
after the 6th hour. Subdivision of these deaths by age 
found apparently opposite eﬀ ects in young children and 
older patients in Chittagong: seven versus 19 in young 
children (in whom such a large beneﬁ t from 
100 mg artesunate is unlikely, in view of the results in 
ﬁ gure 4 for African children) and 22 versus nine in older 
patients (in whom direct hazard from 400 mg artesunate 
is unlikely, in view of the signiﬁ cant beneﬁ ts of artesunate 
over quinine in a large multicentre trial11 among Asian 
patients, many in Chittagong). Drug packaging reversal 
was excluded by post-trial analyses of the remaining 
400 mg capsules.
Pre-referral treatment of older patients might have 
made a few patients less likely to complete hospital 
treatment (table 4), but had little overall eﬀ ect on the 
mean duration of hospital stay. It could not have 
materially aﬀ ected treatment-seeking behaviour in those 
in Asia who reached hospital within 6 h, because their 
median time to arrival was only 2 h. If substantial beneﬁ t 
and hazard are both unlikely, then the most trustworthy 
Risk of death in 0–6 h 
(median 2 h) for all patients
Risk of later death/disability (if survived >6 h)*
Reached clinic in 0–6 h? 
Artesunate Placebo Yes (~3 h†) No (~15 h‡)
Artesunate Placebo Artesunate Placebo
Patients not in coma, by site
Africa (age 6–72 months)
Handeni, Tanzania 11/625 10/629 12/246 14/255 11/368 23/364
Kilosa, Tanzania 7/1153 5/1148 8/535 9/534 8/611 9/609
Navrongo, Ghana 3/974 6/942 12/696 14/692 2/275 3/244
All in Africa 21/2752 (0·8%) 21/2719 (0·8%) 32/1477 (2·2%) 37/1481 (2·5%) 21/1254 (1·7%) 35/1217 (2·9%)
Chittagong, Asia (by age)
6–72 months 2/934 1/901 4/870 13/842 0/62 4/58
Older aged/adult 4/1889 4/1893 §15/1755 §4/1776 0/130 0/113
All in Asia 6/2823 (0·2%) 5/2794 (0·2%) 19/2625 (0·7%) 17/2618 (0·6%) 0/192 (0%) 4/171 (2·3%)
All patients not in coma
Total, Africa and Asia 27/5575 (0·5%) 26/5513 (0·5%) 51/4102 (1·2%) 54/4099 (1·3%) 21/1446 (1·5%) 39/1388 (2·8%)
p value¶ 1·0 0·76 0·0121
Corresponding numbers for patients who were in coma at entry can be obtained by subtracting this table from table 3. *Denominators=numbers surviving more than 
6 h after entry, subdivided by whether patient reached clinic in 0–6 h. Time to clinic was recorded in all who died or had neurological damage; otherwise, it was recorded 
routinely only in Kilosa and Navrongo. For those who did not die in Handeni and Chittagong, it was recorded whether they reached a clinic. For this table it is assumed that, if 
they did die, the proportions doing so in 0–6 h were 50% in Handeni and 95% in Chittagong. †For those who reached clinic in 0–6 h and then died after hour 6, median time 
to arrival was 2 h in Chittagong and 4 h in Africa. ‡For those still not in clinic after more than 6 h who died, the median time to reach clinic (or to death without reaching 
clinic) was 15 h. §Includes six artesunate and one placebo patients who were treated rapidly in hospital, left prematurely against medical advice, then died several days later. 
(One comatose artesunate-allocated adult patient did likewise). ¶p value for artesunate versus placebo.
Table 4: Non-comatose patients only: eﬀ ects of trial treatment (artesunate or placebo) on death or permanent disability, subdivided by time taken to 
reach clinic
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evidence is probably that from the overall results, not 
subdivided by age (ﬁ gures 3 and 4).
The number that need to be treated to avoid one death 
depends on the type of patient. In patients who took 
several hours to reach clinic, pre-referral rectal artesunate 
reduced the risk of death or permanent disability by 
about half in the particular circumstances of this study. 
The analyses, however, excluded patients with suspected 
severe malaria who had a negative blood smear, in whom 
no beneﬁ t of artesunate was expected (or observed; 
ﬁ gure 1). If used without a rapid diagnostic test, the 
absolute beneﬁ t would depend on the proportion of 
suspected malaria that really is malaria. Since only about 
three-quarters of all blood smears in this study were 
positive, the absolute gain among all patients with 
suspected severe malaria who were several hours from 
clinic would be only about 1·4% (ie, three-quarters 
of 1·9%). The absolute gain in patients who actually have 
severe malaria depends, however, on their absolute risk 
(eg, ﬁ gure 5). In those still not in clinic after more 
than 6 h, the background risks of death or permanent 
disability in young children varied substantially between 
the four study sites (from 2% to 8%, with an overall 
mean of 4%). When the background risk is higher than 
in any of these study sites and referral even more 
diﬃ  cult, the absolute beneﬁ t would be considerably 
greater than 1·4%, and could well be much greater 
than 2%. A 100 mg rectal artesunate capsule costs only 
about US$0·10–0·15 to manufacture, so in such 
circumstances it could be very cost eﬀ ective.
The main concern about any type of community 
treatment of suspected severe malaria is that it could 
interfere with referral and proper clinical management. 
One dose of artesunate will not cure severe malaria, and 
widespread use of rectal artesunate without further 
consolidation treatment that is curative could favour the 
development of resistance.12,13 Referral remains important 
both to complete the treatment of malaria and to diagnose 
any other underlying life-threatening infection. (Even in 
the present study with trained recruiters, a quarter [of 
whom 3% died: ﬁ gure 1] did not have malaria.) For 
referral, appropriate health-care facilities need to be 
functioning reliably and accessible.
The ideal is for appropriate oral artesunate combination 
treatment to be aﬀ ordably available14 and used in time to 
prevent uncomplicated disease from becoming severe. 
But, for the foreseeable future, there will be many 
patients in the community with suspected severe 
malaria who could, if treated earlier, have been managed 
orally, but can no longer be treated orally and need 
immediate help. This study shows that referral alone is 
not enough (unless the patient reaches medical care 
very quickly) and that rectal artesunate is acceptable, 
eﬀ ective, and safe. Moreover, it could also be used in 
clinics, reducing the need for injections. Indeed, 
widespread use in clinics might facilitate widespread 
use in the community.
While the study was in progress, compliance with the 
advice to go immediately to a clinic was remarkably 
high both in Africa and in Asia,15–17 partly because there 
was a recruiter in every village and communities were 
continually educated about malaria. Additionally, 
patients in Bangladesh were given a blood slide to take 
with them to hospital, and on arrival they were to be 
admitted and treated immediately free of charge with 
intravenous quinine, broad spectrum antibiotics, and 
good supportive care. Hence, in the 149 Bangladesh 
study areas there was an increase in adherence to 
referral advice from 12% just before the trial18 to 
98% during the trial, a median delay of only about 
2 h between randomisation and reaching eﬀ ective 
treatment in hospital and, overall, only 1·5% mortality 
(and no permanent disability). This shows, importantly, 
that accessible clinics and good organisation within 
villages and within hospitals can greatly reduce malaria 
mortality and morbidity even without pre-referral 
treatment.
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